Introduction
Sulfatides are anionic sulfoglycolipids mainly found in the outer leaflet of the plasma membranes of cells (1, 2) . Sulfatides are particularly abundant in the brain, where they constitute an important component of myelin. Oligodendrocytes are responsible for the synthesis of sulfatides and the maintenance of sulfatide levels in myelin (1) . However, recent studies in mice indicate, that their presence is not restricted to oligodendrocytes and Schwann cells, but they are also present in neurons and astrocytes (3) . Sulfatides are also components of extra neural tissues and high concentrations are found in selected organs including kidney, colon, pancreas and gall bladder. Increased concentrations of sulfatides have been reported in renal cell carcinoma, adenocarcinoma of colon and lung and ovarian cancer (2, 4) . Sulfatides have been proposed to play a role as ion barriers to osmotic stress and as counter ions of ammonium in the renal adaptation to chronic metabolic acidosis (5, 6) Sulfatides are synthesized from their precursor galactosylceramide in the Golgi apparatus by 3-O-sulfation of the galactose residue by the enzyme 3'-phosphoadenosine-5'-phosphosulfate: cerebroside sulfotransferase (CST; EC2.8.2.11). Galactosylceramide is synthesized in the endoplasmic reticulum from ceramides and UDP-galactose by the enzyme UDP-galactose:ceramide galactosyltransferase (CGT; EC 2.4.1.45) and then transported to the Golgi apparatus prior to sulfation to sulfatides. Sulfatides consist of many molecular species with structures differing in acyl chain length and hydroxylation and sphingoid base. These sulfatide molecular species are cell and tissue specific which may be explained by the cell and tissue specific expression of ceramide synthases and fatty acid 2-hydroxylase (1, 7) . It is difficult to assign specific functions to the different molecular species of sulfatides, but sulfatides with C16:0 fatty acids were reported to be involved in the regulation of insulin secretion in rat pancreatic β-cells (8) , and elevated levels of C18:0 sulfatides have been implicated as a cause of audiogenic seizers in mice overexpressing CGT (9) . There is also heterogeneity of the sphingoid base composition of sulfatides. Most of the sulfatides contain 4-sphingenine (sphingosine, d18:1), but the presence of sphingadienine (d18 :2) has been reported in mammalian brain (10) .
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Degradation of sulfatides takes place in the lysosomes and is catalyzed by the lysosomal enzyme arylsulfatase A (ASA; EC 3.1.6.8). An accessory protein saposin B, a so called sphingolipid activator protein, is required for the lysosomal degradation of sulfatides by ASA. A deficiency of ASA or of saposin B leads to intra lysosomal storage of sulfatides and is the cause of the lysosomal storage disease metachromatic leukodystrophy (11) . Besides storage of sulfatides also lysosulfatide, the deacylated form of sulfatides, accumulates in tissues of patients with metachromatic leukodystrophy (12) . The accumulation of sulfatides in kidney leads to an increased excretion of sulfatides in urine. Determination of sulfatides in urine is a convenient diagnostic tool to confirm metachromatic leukodystrophy in patients with arylsulfatase A deficiency or saposin B deficiency (13) (14) (15) . Next to mutation analysis of the ASA gene it is also used to confirm a pseudodeficiency of arylsulfatase A. Severe demyelination is an important feature of metachromatic leukodystrophy in humans (11) . A mouse model of arylsulfatase A deficiency was created by targeted disruption of the ASA gene (16) . This model was extensively characterized and exhibits many features of human metachromatic leukodystrophy including storage of sulfatides and lysosulfatide (3, 17) . However, in contrast to the human disease, this mouse model of metachromatic leukodystrophy does not show demyelination (3, 16) . Demyelination could be induced in ASA knockout mice overexpressing CGT, presumably by increasing the substrate load in the lysosomes that lack the ability to degrade sulfatides (18).
Several methods have been used to quantify sulfatides including TLC (19) , HPLC (14, 20) and more recently mass spectrometry (4, 13, 15, (21) (22) (23) (24) (25) . Here we describe a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to quantify sulfatides and their molecular species over a wide range of concentrations in normal and diseased tissues, plasma and urine. In addition we describe a sensitive and facile LC-MS/MS method for the quantification of lysosulfatides in the same tissues.

Experimental procedures
Materials
LC-MS-grade methanol, water and HPLC-grade chloroform were purchased from Biosolve, ammonium formate LC-MS grade from Sigma-Aldrich, ammonium hydroxide and ammonia solution (25%) from Merck, silica Gel (SiOH) for SPE columns from Bakerbond.
Lipid Standards
Lysosulfatide, N-Acetyl-sulfatide and N-Octadecanoyl-D3-sulfatide were obtained from Matreya LLC. Bovine brain sulfatides were from Sigma-Aldrich.
Animals
Twenty month old wild type (+/+) C57BL/6J and ASA knock out (-/-) mice carrying the human ASA-C96S transgene to make them immune-tolerant to human arylsulfatase A were used in this study (26) .
Patient and Control samples
Urine and plasma samples were obtained from patients with metachromatic leukodystrophy during diagnostic work-up or follow-up. Informed consent was obtained from all patients or their guardians. 
Extraction of sulfatides from human urine
Sulfatides were extracted from urine by a modification of the method of Folch (27) . Briefly, to 0.5 mL of urine in a 5 mL glass tube 25µL of internal standard N-Octadecanoyl-D3-sulfatide (10 nmol/mL in chloroform/methanol, 1:2, v/v) was added (final concentration 0.5 nmol/mL urine) and stirred briefly.
Then, 2 mL chloroform:methanol (2:1) was added with brief stirring, and centrifuged for 5 min at 3220 x g. The lower phase was transferred to a clean glass tube. The upper phase was re-extracted by addition of 1.3 ml chloroform and pooled with the first lower phase. Recovery of the sulfatides in the combined lower phases was >95%. The combined lower phases were dried under a gentle stream of nitrogen at 35 °C and the residue was dissolved in 500µL chloroform:methanol (98:2). This total lipid extract was subsequently fractionated on Bakerbond Silica Gel (SiOH) SPE columns using vacuum assisted flow (1mL, 100 mg per column). The columns were conditioned by consecutive washes with 2 mL methanol, 2 mL chloroform:methanol (1:1, v/v) and 2 mL chloroform. Subsequently samples were loaded onto the column and the sample tube was rinsed with 200 µL chloroform:methanol (98:2, v/v) which was also loaded onto the column. Lipids were fractionated by a modified procedure (28) by eluting the column with 2 mL of chloroform:methanol (98:2, v/v, fraction 1), 1 mL acetone:methanol (90:10, v/v) (fraction 2). The recovery of sulfatides in fraction 2 with this method is >90 %. The phospholipids which remain bound to the column can be eluted with 100 % methanol (fraction 3). The fractionation on SPE serves as a clean-up step of the urinary extract to reduce matrix effects and reduce contamination of the UPLC-column and the mass spectrometer.
Preparation of tissue homogenates
Tissue homogenates (brain, liver and kidney) were prepared in water (1 part of tissue 3 parts water v/v).
The tissues were cut into small pieces with a scissor prior to sonication 3 x 5 seconds on melting ice. After vortexing (1 minute) the homogenate was sonicated again, 2 x 5 seconds. The homogenates from brain and kidney from ASA knockout mice and brain from wild type mice were diluted 10 fold in water prior to extraction.
Extraction of sulfatides from plasma and tissue homogenates
50µL of plasma, 25µL of brain, 25µL of kidney and 100µL of liver homogenates were used for extraction.
N-Octadecanoyl-D3-sulfatide was added as the internal standard at 4 nmol/mL for mouse plasma, 2 nmol/mL for human plasma, 200 nmol/mL for the brain homogenates, 200 nmol/mL and 120 nmol/mL for the kidney homogenates of ASA knockout and wild type mice, 5 nmol/mL and 3 nmol/mL for liver homogenates from ASA knockout and wild type mice. Plasma and tissues were extracted by a modification of the method of Folch (27) as described here for a 50 µL sample. The sample was pipetted into a 5 mL glass tube, 1 mL methanol was added and stirred briefly. Subsequently 1 mL of chloroform was added and stirred for 1 minute. The sample was incubated 30 min at room temperature and stirred occasionally, then centrifuged 10 min at 3220 x g to remove protein. The supernatant was transferred into a glass tube to which 1 mL chloroform and 0.75 mL water were added, mixed and centrifuged for 2 min at 3220 x g. The lower phase was transferred to a glass tube and the upper phase was re-extracted with 1.8 mL of chloroform which was pooled with the first lower phase. The combined lower phases were dried, redissolved and fractioned by SPE as described above for the urine samples. Fractionation has a strong influence on the signal intensity of all molecular species of sulfatides in plasma, which increased by a factor of 2-3 as a result of diminished ion suppression. An example is given in Table 4 of the supplemental data, where we discuss the precursor spectra of m/z 96.9 in plasma of an MLD patient with and without fractionation of the lipid extract on SPE. In addition, the removal of phospholipids decreases the contribution precursors of m/z 96.9 due to HPO3 -ions. This leads to an increase in the reliability of the annotation of the sulfatide species.
Extraction of lysosulfatide from plasma and tissue
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Lysosulfatide was extracted from plasma and mouse tissue homogenates (same sample volumes as described for sulfatide) by a modification of the method of Bligh and Dyer (29) . Briefly, 50 µL sample was pipetted in an Eppendorf tube, internal standard (N-acetyl-sulfatide, 0.1 nmol/mL in methanol) (30) was added, mixed briefly. Subsequently, 25 µL water, 300 µL methanol, and 150 µL chloroform were added with 1 min mixing after each addition. The samples were left for 30 min at room temperature. After centrifugation for 10 min at 15700 x g to spin down precipitated protein, the supernatants were transferred to Eppendorf tubes and 150 µL chloroform and 225 µL water were added. After mixing, the tubes were centrifuged for 2 min at 15700 x g to separate the phases. From the upper phase, 400 µL was transferred to a 2 mL tube. The lower phase was re-extracted by addition of 300 µL methanol and 300 µL water, which 
Sample preparation for mass spectrometry
For the sulfatides, Fraction 2 from the SPE column was dried under a nitrogen stream at 35ºC and dissolved in 100µL methanol prior to LC-MS/MS analysis. For lysosulfatide, dried upper phases were redissolved in 100 µL methanol, vortexed for 1 min, and sonicated for 30 s in a bath sonifier. The samples were centrifuged for 10 min at 15700 x g to precipitate any insoluble material prior to LC-MS/MS analysis. For direct infusion measurements dried upper or lower phases were re-dissolved in 500 µL 1% ammonium hydroxide in chloroform:methanol (1:2, v/v), and centrifuged for 1 min at 15700 x g to remove insoluble material.
Instrumentation and data analysis
An Acquity UPLC (Waters) coupled to a tandem quadrupole mass spectrometer (TQD, Waters) was used for all analyses. Data were analysed with Masslynx Software (Waters), for the identification and quantification of sulfatides in direct infusion experiments we used the Lipid Mass Spectrum Analysis (LIMSA) program (31).
Measurement of sulfatides and lysosulfatides by tandem mass spectrometry
The instrument settings for the detection of sulfatides and lysosulfatides were optimized by measuring pure standards (Lysosulfatide, N-Acetyl-sulfatide and N-Octadecanoyl-D3-sulfatide) by direct infusion into the mass spectrometer. Optimal conditions for collision-induced dissociation were established for transitions m/z 888.7 > 96.9 and 890.7 > 96.9 for sulfatides and m/z 540.4 > 96.9 for lysosulfatide and are given in Table 1 (Table 3 of the Supplemental data).
Separation of sulfatides by reversed phase UPLC
Sulfatides were separated on a BEH C18 reversed-phase column (2.1x50 mm, particle size 1.7 µm, Waters) by applying a gradient from methanol:water 37:63 v/v, with 5 mM ammonium formate (Eluent A) to methanol, 5 mM ammonium formate (Eluent B) at 0.350 ml/min. During the 11.5 minute programme a linear gradient was applied from 0% to 100% eluent B in 2.5 minutes and kept at 100% B until 10 minutes, before going back to 0% B at 11 minutes. The eluent was diverted to waste between 0.00 and Table 3 of the Supplemental data . Sulfatides elute in order of decreasing polarity i.e. molecular species were separated according to chain length of the fatty acids with molecular species with the shortest chain length eluting first. For each carbon chain length of the fatty acid the molecular species of the sulfatides eluted in the order: monounsaturated fatty acids containing molecular species first, then hydroxy fatty acid containing molecular species and finally the saturated fatty acid containing molecular species.
Separation of lysosulfatides by reversed phase UPLC
Lysosulfatides were separated using the same column and mobile phases as for the sulfatides. A linear gradient was applied during a 5.50 minute programme from 0% to 100% B in 2.50 minutes and kept at 100% B until 4.00 minutes before going back to 0% B at 5.00 minutes. The flow rate was 0.250 mL/min.
The eluent was diverted to waste between 0.00 and 2.30 minutes and after 4.05 minutes to keep the source free of contaminants, data were collected between 2.30 and 4.05 minutes. The retention times of the lysosulfatides and the internal standard are shown in Table 3 of the Supplemental data . were above the control range whereas that of the five late onset patients fell within the control range .
Results
Quantification of total sulfatides in human urine and plasma
Control
The range of sulfatide concentrations in plasma of all MLD patients tested was 0.8-3.3 µM (n=9). The limit of quantification is 8 pmol/mL (S/N ratio > 10).
Quantification of total sulfatides in murine tissues and plasma
Tissue and plasma sulfatides were quantified based on a single point calibration using the sum of the area from 10 major molecular species relative to that of the internal standard N-octadecanoyl-D3-sulfatide. Table 1 show the results of sulfatide analysis of selected tissues and plasma from two normal twenty month old wild type mice (+/+, C57BL/6J) and ASA knockout mice (-/-carrying the human ASA-C96S), (26) . Strongly increased levels of sulfatides were found in brain (~2.6 fold), kidney (~84 fold) and liver (~19 fold) from the ASA knockout mice. These results show the ability of the method to quantify sulfatides over a wide range of concentrations in tissue (at least 7000-fold difference in concentration of control liver vs. ASA knock out brain). The levels of sulfatides in the ASA knockout mice were increased 3-fold in plasma.
Measurement of different molecular sulfatide species in fluids and tissues from human and murine origin.
The use of LC-MS/MS also allows quantification of individual molecular species of sulfatides. Table 2 compares the percentage composition of the molecular species of sulfatides in brain, kidney and liver from control mice (C57BL/6J) and ASA knockout mice (-/-). A characteristic set of 10 major sulfatide species by guest, on October 14, 2017 www.jlr.org
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were found for each organ mainly consisting of long-and very long-chain saturated, mono-unsaturated and hydroxyl-fatty acids. Although no single species was unique for a tissue the relative composition is tissue specific. An exception is C20:0-OH sulfatide (m/z 850.7) which was found to be a major species unique for kidney (15.5 % in ASA knock out vs. 9.5 % in C57BL/6J control mice). The transition m/z 850.7> 96.9 was not routinely included in the set of transitions monitored for the quantification of total sulfatides in tissues (Table 2) leading to a slight underestimation of the sulfatide content in kidney. Only small quantitative differences in the percentage composition are observed between the molecular species in tissues from control mice and ASA knockout mice (-/-). An exception are C16:0 species of sulfatides which were much higher in plasma from ASA knockout mice (-/-) compared to wild type plasma. Table 3 shows the percentage composition of the 13 major molecular species of sulfatide in human plasma and urine. C16:0, C16:0-OH and C24:1 molecular species were higher in MLD plasma compared to human control plasma, while hydroxy fatty acids containing sulfatides were generally lower in MLD plasma. In addition to the molecular species tabulated in Table 3 we observed both in in human plasma and urine a sulfatide species with transition 892.7>96.9 and a retention of 4.80 min., which could not be identified with certainty, but fits best with a C23:0-OH sulfatide species. The percentage of this sulfatide species was 5.7% in control plasma , 4.0 % in MLD plasma, 9.8% in control urine and 7.3% in MLD urine .
Quantification of lysosulfatide in mouse tissues and plasma and human plasma
Mouse tissue and plasma lysosulfatide were quantified based on a single point calibration relative to the area of the internal standard N-acetyl-sulfatide added ( Table 4 ). The method has sufficient sensitivity to reliably quantify lysosulfatide in normal mouse brain. The lysosulfatide levels in brain of the ASA knockout mice is 76 times higher than in the C57BL/6J control mice. Strongly increased levels of lysosulfatide were also observed in kidney and liver of ASA knockout mice, but although lysosulfatide could be detected in the normal control kidney and liver their levels were below the limit of quantification.
In addition to lysosulfatide with a sphingosine base (4-sphingenine, d18:1, RT 3.29 min, m/z 540.4) we consistently observed a lysosulfatide with a molecular mass 2 m/z smaller and a RT of 3.10 minutes. This suggests the presence of a lysosulfatide with a sphingadienine (d18:2) base. This d18:2 species was present at 20 % of the d18:1 lysosulfatide signal intensity in brain and kidney and > 30 % in liver of ASA knockout mice. Lysosulfatide could not be reliably quantified in plasma from normal and ASA knockout mice and plasma from MLD patients and healthy volunteers as its concentration was below the limit of quantification.
Discussion
We developed an LC-MS/MS method for identification and quantitation of sulfatides and lysosulfatides in A consistent, be it rather small difference between sulfatide levels in plasma from age-matched wild type (+/+) C57BL/6J and ASA knockout mice (-/-) was found. (24, 25) In addition to the sulfatide determination we describe the determination of lysosulfatide, the deacylated form of the primary storage product sulfatide by LC-MS/MS for the first time. Previous methods used primarily HPLC methods for detection and quantification of lysosulfatide (12, 17) . Next to sensitivity and specificity our method has advantage of a simple sample clean up procedure compared to previously described methods. This is due to the quantitative partitioning to the polar upper phase in the Bligh and base previously shown to be present in galactosylceramides and sulfatides from mouse brain (10) .
Prompted by the presence of globotriaosylsphingosine in plasma from Fabry mice and human Fabry patients (35, 36) and glucosylsphingosine in plasma from Gaucher mice and human Gaucher patients (37, 
